1 |
Lafferty, K. J. 1994. A contemporary view of transplantation tolerance: An immunologist's perspective. Clin. Transplant. 8: 181-187.
|
2 |
Larsen, C. P., E. T. Elwood, D. Z. Alexander, S. C. Ritchie, R. Hendrix, C. Tucker-Burden, et al. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381: 434-438.
DOI
ScienceOn
|
3 |
Lin, H., R. Q. Wei, D. Gordon, P. Linsley, L. A. Turka, and S. F. Bolling. 1994. Review of CTLA4Ig use for allograft immunosuppression. Transplant. Proc. 26: 3200-3201.
|
4 |
Ling, V., P. W. Wu, H. F. Finnerty, A. H. Sharpe, G. S. Gray, and M. Collins. 1999. Complete sequence determination of the mouse and human CTLA4 gene loci: Cross-species DNA sequence similarity beyond exon borders. Genomics 60: 341-355.
DOI
ScienceOn
|
5 |
Linsley, P. S., W. Brady, M. Urnes, L. S. Grosmaire, N. K. Damle, and J. A. Ledbetter. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174: 561-569.
DOI
ScienceOn
|
6 |
Linsley, P. S. and J. A. Ledbetter. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11: 191-212.
DOI
ScienceOn
|
7 |
Lorenz, H. M. and J. R. Kalden. 2002. Perspectives for TNFalpha-targeting therapies. Arthritis Res. 4 Suppl 3: S17-S24.
DOI
|
8 |
Malm, H., M. Corbascio, C. Osterholm, S. Cowan, C. P. Larsen, T. C. Pearson, and H. Ekberg. 2002. CTLA4Ig induces longterm graft survival of allogeneic skin grafts and totally inhibits T-cell proliferation in LFA-1-deficient mice. Transplantation 73: 293-297.
DOI
ScienceOn
|
9 |
Mastrangeli, R., E. Micangeli, and S. Donini. 1996. Cloning of murine LAG-3 by magnetic bead bound homologous probes and PCR (gene-capture PCR). Anal. Biochem. 241: 93-102.
DOI
ScienceOn
|
10 |
Moreland, L. W., R. Alten, F. Van den Bosch, T. Appelboom, M. Leon, P. Emery, et al. 2002. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, doubleblind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 46: 1470-1479.
DOI
ScienceOn
|
11 |
Murphy, W. J. and B. R. Blazar. 1999. New strategies for preventing graft-versus-host disease. Curr. Opin. Immunol. 11: 509-515.
DOI
ScienceOn
|
12 |
Naparstek, Y. and P. H. Plotz. 1993. The role of autoantibodies in autoimmune disease. Annu. Rev. Immunol. 11: 79-104.
DOI
ScienceOn
|
13 |
Petric, R., D. Freeman, C. Wallace, J. McDonald, C. Stiller, and P. Keown. 1988. Effect of cyclosporine on urinary prostanoid excretion, renal blood flow, and glomerulotubular function. Transplantation 45: 883-889.
DOI
ScienceOn
|
14 |
Przepiorka, D., G. L. Phillips, V. Ratanatharathorn, M. Cottler-Fox, L. H. Sehn, J. H. Antin, et al. 1998. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood 92: 4066-4071.
|
15 |
Reiter, Y. and I. Pastan. 1998. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol. 16: 513-520.
DOI
ScienceOn
|
16 |
Rodrigues, M., R. S. Nussenzweig, P. Romero, and F. Zavala. 1992. The in vivo cytotoxic activity of CD8+ T cell clones correlates with their levels of expression of adhesion molecules. J. Exp. Med. 175: 895-905.
DOI
ScienceOn
|
17 |
Schwartz, R. H. 1992. Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71: 1065-1068.
DOI
ScienceOn
|
18 |
Scott, D. L. 2005. Etanercept in arthritis. Int. J. Clin. Pract. 59: 114-118.
DOI
ScienceOn
|
19 |
Subramanyam, M., G. Wands, R. Nabioullin, and M. A. Tepper. 1998. Soluble human lymphocyte activation gene-3 modulates allospecific T cell responses. Int. Immunol. 10: 679-689.
DOI
ScienceOn
|
20 |
Storb, R., R. B. Epstein, T. C. Graham, and E. D. Thomas. 1970. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 9: 240-246.
DOI
ScienceOn
|
21 |
Sultan, P., J. S. Schechner, J. M. McNiff, P. S. Hochman, C. C. Hughes, M. I. Lorber, et al. 1997. Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Nat. Biotechnol. 15: 759-762.
|
22 |
Suthanthiran, M. and T. B. Strom. 1994. Renal transplantation. N. Engl. J. Med. 331: 365-376.
DOI
ScienceOn
|
23 |
Triebel, F., S. Jitsukawa, E. Baixeras, S. Roman-Roman, C. Genevee, E. Viegas-Pequignot, and T. Hercend. 1990. LAG-3, a novel lymphocyte activation gene closely related to CD4. J. Exp. Med. 171: 1393-1405.
DOI
ScienceOn
|
24 |
Via, C. S. and G. M. Shearer. 1988. T-cell interactions in autoimmunity: Insights from a murine model of graft-versushost disease. Immunol. Today 9: 207-213.
DOI
ScienceOn
|
25 |
Wallace, P. M., J. S. Johnson, J. F. MacMaster, K. A. Kennedy, P. Gladstone, and P. S. Linsley. 1994. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 58: 602-610.
DOI
ScienceOn
|
26 |
Wang, Q., M. Zhang, G. Ding, Y. Liu, Y. Sun, J. Wang, et al. 2003. Anti-ICAM-1 antibody and CTLA-4Ig synergistically enhance immature dendritic cells to induce donor-specific immune tolerance in vivo. Immunol. Lett. 90: 33-42.
DOI
ScienceOn
|
27 |
Yamane, T., R. Yamamura, Y. Aoyama, H. Nakamae, T. Hasegawa, C. Sakamoto, et al. 2003. Infliximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leuk. Lymphoma 44: 2095-2097.
DOI
ScienceOn
|
28 |
Woodward, J. E., L. Qin, K. D. Chavin, J. Lin, T. Tono, Y. Ding, et al. 1996. Blockade of multiple costimulatory receptors induces hyporesponsiveness: Inhibition of CD2 plus CD28 pathways. Transplantation 62: 1011-1018.
DOI
ScienceOn
|
29 |
Wu, A. M., W. Chen, A. Raubitschek, L. E. Williams, M. Neumaier, R. Fischer, et al. 1996. Tumor localization of anti-CEA single-chain Fvs: Improved targeting by non-covalent dimers. Immunotechnology 2: 21-36.
DOI
ScienceOn
|
30 |
Wu, A. M., P. J. Yazaki, S. Tsai, K. Nguyen, A. L. Anderson, D. W. McCarthy, et al. 2000. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc. Natl. Acad. Sci. USA 97: 8495-8500.
DOI
ScienceOn
|
31 |
Yim, S. B. and Y. H. Chung. 2004. Construction and production of concatameric human TNF receptor immunoglobulin fusion proteins. J. Microbiol. Biotechnol. 14: 81-89.
|
32 |
Yin, D. and C. G. Fathman. 1995. Induction of tolerance to heart allografts in high responder rats by combining anti-CD4 with CTLA4Ig. J. Immunol. 155: 1655-1659.
|
33 |
Yu, C., P. Linsley, K. Seidel, G. Sale, H. J. Deeg, R. A. Nash, and R. Storb. 2000. Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-nonidentical marrow transplant model. Transplantation 69: 450-454.
DOI
ScienceOn
|
34 |
Benito, A. I., T. Furlong, P. J. Martin, C. Anasetti, F. R. Appelbaum, K. Doney, et al. 2001. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 72: 1924-1929.
DOI
ScienceOn
|
35 |
Adams, A. B., N. Shirasugi, M. M. Durham, E. Strobert, D. Anderson, P. Rees, et al. 2002. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 51: 265-270.
DOI
ScienceOn
|
36 |
Adams, G. P., C. C. Shaller, L. L. Chappell, C. Wu, E. M. Horak, H. H. Simmons, et al. 2000. Delivery of the alphaemitting radioisotope bismuth-213 to solid tumors via singlechain Fv and diabody molecules. Nucl. Med. Biol. 27: 339-346.
DOI
ScienceOn
|
37 |
Antin, J. H. and J. L. Ferrara. 1992. Cytokine dysregulation and acute graft-versus-host disease. Blood 80: 2964-2968.
|
38 |
Bierer, B. E., G. Hollander, D. Fruman, and S. J. Burakoff. 1993. Cyclosporin A and FK506: Molecular mechanisms of immunosuppression and probes for transplantation biology. Curr. Opin. Immunol. 5: 763-773.
DOI
ScienceOn
|
39 |
Blazar, B. R., P. A. Taylor, A. Panoskaltsis-Mortari, G. S. Gray, and D. A. Vallera. 1995. Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 85: 2607-2618.
|
40 |
Blazar, B. R., P. A. Taylor, P. S. Linsley, and D. A. Vallera. 1994. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 83: 3815-3825.
|
41 |
Bluestone, J. A., E. W. St Clair, and L. A. Turka. 2006. CTLA4Ig: Bridging the basic immunology with clinical application. Immunity 24: 233-238.
DOI
ScienceOn
|
42 |
Capon, D. J., S. M. Chamow, J. Mordenti, S. A. Marsters, T. Gregory, H. Mitsuya, et al. 1989. Designing CD4 immunoadhesins for AIDS therapy. Nature 337: 525-531.
DOI
ScienceOn
|
43 |
Comoli, P., F. Locatelli, A. Moretta, D. Montagna, V. Calcaterra, A. Cometa, et al. 2001. Human alloantigen-specific anergic cells induced by a combination of CTLA4-Ig and CsA maintain anti-leukemia and anti-viral cytotoxic responses. Bone Marrow Transplant. 27: 1263-1273.
DOI
ScienceOn
|
44 |
Economides, A. N., L. R. Carpenter, J. S. Rudge, V. Wong, E. M. Koehler-Stec, C. Hartnett, et al. 2003. Cytokine traps: Multicomponent, high-affinity blockers of cytokine action. Nat. Med. 9: 47-52.
|
45 |
Emery, P. 2003. The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. Expert Opin. Investig. Drugs 12: 673-681.
DOI
ScienceOn
|
46 |
Goldenberg, M. M. 1999. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin. Ther. 21: 75-87; discussion 1-2.
DOI
ScienceOn
|
47 |
Guidotti, L. G. and F. V. Chisari. 2000. Cytokine-mediated control of viral infections. Virology 273: 221-227.
DOI
ScienceOn
|
48 |
Gottlieb, A. B. 2004. Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatol. Ther. 17: 401-408.
DOI
ScienceOn
|
49 |
Grakoui, A., S. K. Bromley, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen, and M. L. Dustin. 1999. The immunological synapse: A molecular machine controlling T cell activation. Science 285: 221-227.
DOI
ScienceOn
|
50 |
Gratama, J. W., J. Jansen, R. A. Lipovich, H. J. Tanke, G. Goldstein, and F. E. Zwaan. 1984. Treatment of acute graftversus-host disease with monoclonal antibody OKT3. Clinical results and effect on circulating T lymphocytes. Transplantation 38: 469-474.
DOI
ScienceOn
|
51 |
Guinan, E. C., J. G. Gribben, V. A. Boussiotis, G. J. Freeman, and L. M. Nadler. 1994. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84: 3261-3282.
|
52 |
Guy-Grand, D., M. Dy, G. Luffau, and P. Vassalli. 1986. Gut mucosal mast cells: Origin, traffic and differentiation in mice and rats. Ann. Inst. Pasteur Immunol. 137D: 215-222.
|
53 |
Hale, D. A., R. Gottschalk, T. Maki, and A. P. Monaco. 1997. Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival. Transplantation 64: 897-900.
DOI
ScienceOn
|
54 |
Hanahan, D. 1983. Studies on transformation of Escherichia coli with plasmids. J. Mol. Biol. 166: 557-580.
DOI
|
55 |
Harlan, D. M., R. Abe, K. P. Lee, and C. H. June. 1995. Potential roles of the B7 and CD28 receptor families in autoimmunity and immune evasion. Clin. Immunol. Immunopathol. 75: 99-111.
DOI
ScienceOn
|
56 |
Jacobsohn, D. A. and G. B. Vogelsang. 2002. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs 62: 879-889.
DOI
ScienceOn
|
57 |
Harty, J. T., A. R. Tvinnereim, and D. W. White. 2000. CD8+ T cell effector mechanisms in resistance to infection. Annu. Rev. Immunol. 18: 275-308.
DOI
ScienceOn
|
58 |
Huard, B., P. Prigent, F. Pages, D. Bruniquel, and F. Triebel. 1996. T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding. Eur. J. Immunol. 26: 1180-1186.
DOI
ScienceOn
|
59 |
Huard, B., M. Tournier, T. Hercend, F. Triebel, and F. Faure. 1994. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. Eur. J. Immunol. 24: 3216-3221.
DOI
ScienceOn
|
60 |
Kaplon, R. J., P. S. Hochman, R. E. Michler, P. A. Kwiatkowski, N. M. Edwards, C. L. Berger, et al. 1996. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. Transplantation 61: 356-363.
DOI
ScienceOn
|
61 |
Kirk, A. D., D. M. Harlan, N. N. Armstrong, T. A. Davis, Y. Dong, G. S. Gray, et al. 1997. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. USA 94: 8789-8794.
DOI
ScienceOn
|
62 |
Kortt, A. A., O. Dolezal, B. E. Power, and P. J. Hudson. 2001. Dimeric and trimeric antibodies: High avidity scFvs for cancer targeting. Biomol. Eng. 18: 95-108.
DOI
ScienceOn
|
63 |
Krieger, N. R., D. Yuh, W. B. McIntyre, T. F. Flavin, D. Yin, R. Robbins, and C. G. Fathman. 1998. Prolongation of cardiac graft survival with anti-CD4Ig plus hCTLA4Ig in primates. J. Surg. Res. 76: 174-178.
DOI
ScienceOn
|